Theralase Technologies (TLT) Corporate presentation summary

Scientific and clinical research

• Developed small molecules over 22 years to target cancers, bacteria, and viruses while sparing healthy cells.

• Preclinical research shows high safety and efficacy against herpes lesions, glioblastoma, lung cancer, leukemia, lymphoma, and myeloma.

• Phase II NMIBC clinical study enrolled 82 patients, with 69 completing; interim data shows 62.3% complete response and 100% safety.

• FDA Fast Track Designation granted for NMIBC clinical study.

• Management team has extensive experience in drug discovery, clinical development, and commercialization.

Intellectual property and technology

• Holds 29 issued patents and 17 pending for small molecules and formulations globally.

• Patents protect Ruvidar® and Rutherrin® in major markets, with key patents expiring between 2033 and 2036, extendable under Hatch-Waxman Act.

• Proprietary laser systems and multiwavelength photodynamic therapy are protected.

Product pipeline and mechanism of action

• Ruvidar® (TLD-1433) is a ruthenium-based molecule designed to destroy solid tumors and viruses, enhanced by energy activation.

• Drug and device pipelines target NMIBC, HSV-1, glioblastoma, NSCLC, pancreatic, colorectal, and hematologic cancers.

• Mechanism exploits cancer cells’ higher iron uptake via transferrin receptors, enabling selective targeting and destruction.

• Ruvidar® and Rutherrin® induce immunogenic cell death in cancer cells, sparing healthy tissue.